Clinical Trial Update: to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating eltrombopag for immune thrombocytopenia in patients with chronic hepatitis B infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Thrombocytopenia Purpura, Chronic HBV Infection | Phase 2 | Status: COMPLETED